ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Hospital Universitario La Paz
Madrid, EspañaHospital Universitario La Paz-ko ikertzaileekin lankidetzan egindako argitalpenak (10)
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
2014
-
Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk
European Journal of Cancer, Vol. 50, Núm. 18, pp. 3168-3177
2013
-
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study
Journal of Clinical Oncology
-
Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population
BMC Cancer, Vol. 13
-
rs12512631 on the Group Specific Complement (Vitamin D-Binding Protein GC) Implicated in Melanoma Susceptibility
PLoS ONE, Vol. 8, Núm. 3
2012
-
Role of glutathione S-transferases in melanoma susceptibility: Association with GSTP1 rs1695 polymorphism
British Journal of Dermatology, Vol. 166, Núm. 6, pp. 1176-1183
2011
-
A customized pigmentation snp array identifies a novel snp associated with melanoma predisposition in the slc45a2 gene
PLoS ONE, Vol. 6, Núm. 4
-
Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility
European Journal of Cancer, Vol. 47, Núm. 17, pp. 2618-2625